Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens

Kosmas, Christos; Tsavaris, Nicolas; Panopoulos, C; Vadiaka, Maria; Stavroyianni, Niki; Kourelis, Th; Malamos, Nikos; Antonopoulos, Minas J.; Kalofonos, Haralabos P.

doi:10.1016/s0959-8049(00)00419-6

Cited by 34 publications

(13 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The aim of this study was to investigate the feasibility and effectiveness of third-generation chemotherapy with bevacizumab. Vinorelbine was selected as the other third-generation chemotherapeutic agent, as it is a vinca alkaloid with barely any reported adverse events in previous second-line studies (21). In terms of adverse events, there was a high rate of severe phlebitis.…”

Section: Discussionmentioning

confidence: 99%

A feasibility study of bevacizumab and vinorelbine in patients with previously treated advanced non-squamous non-small-cell lung cancer

Kaburaki

Isobe

Kobayashi

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

A feasibility study of bevacizumab and vinorelbine in patients with previously treated advanced non-squamous non-small-cell lung cancer

Kaburaki

Isobe

Kobayashi

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

“…Single-agent paclitaxel (Socinski et al, 1999), docetaxel (Fossella et al, 2000;Shepherd et al, 2000) and gemcitabine (Baas et al, 1999;Rossi et al, 1999) have been investigated in the second-line setting. In addition, several phase II studies have evaluated different drug combinations in the second-line setting (Androulakis et al, 1999;Herbst et al, 1999;Herrero et al, 2000;Kosmas et al, 2001;Leu et al, 2001;Laack et al, 2002) The data from these studies strongly suggest that, although response rates may be higher when a combination regimen is used second line, the median overall survival ranges from 6 to 8 months, which is not significantly different from that observed with single agents.…”

Section: Discussionmentioning

confidence: 99%

Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study

et al. 2004

View full text Add to dashboard Cite

To compare irinotecan (CPT-11) þ gemcitabine vs CPT-11 alone as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC) progressing after docetaxel -cisplatinum-based therapy. A total of 147 evaluable, pretreated patients, with NSCLC, received either gemcitabine (1000 mg m À2 , days 1 and 8) þ CPT-11 (300 mg m À2, day 8) (Group A, n ¼ 76) or CPT-11 (300 mg m À2 , day 1) (Group B, n ¼ 71), every 3 weeks. All patients were evaluable for response and toxicity. The objective response rate was 18.4% (95% CI: 9.71 -27.14%) and 4.2% (95% CI: 0 -8.90%) (P ¼ 0.009) for groups A and B, respectively. No significant differences between the two groups in terms of the median duration of response, time to tumour progression, overall survival and 1-year survival were observed. The CPT-11/gemcitabine regimen significantly improved the patients' quality of life ('general mood today' (P ¼ 0.014), 'coughing' (P ¼ 0.003) and 'intensity of symptoms' (P ¼ 0.034)) compared with CPT-11. More cycles had to be delayed (P ¼ 0.001) and required prophylactic growth factor support (P ¼ 0.001) in Group A than B. Three (3.9%) patients in Group A and eight (11.3%) in Group B developed febrile neutropenia (P ¼ 0.09); one patient died of sepsis in each group. Three additional (Group A, n ¼ 1; Group B, n ¼ 2) treatment-related deaths were observed. Grade 3 -4 haematologic toxicity was comparable in the two groups except anaemia (P ¼ 0.03 in favour of CPT-11). Other nonhaematologic toxicities were mild and similar in the two groups. CPT-11 þ gemcitabine resulted in a higher response rate and better control of disease-related symptoms than CPT-11 alone, but without any improvement in the overall survival.

show abstract

“…Also, there have been trials for frontline gemcitabine and vinorelbine (GV) combination chemotherapy in elderly patients [13,14]. Given a good safety profile and a high activity as the frontline treatment of advanced NSCLC, GV combination regimens as salvage chemotherapy have been evaluated [15,16,17]. However, most previous studies on salvage GV regimens had enrolled younger patients.…”

Section: Introductionmentioning

confidence: 99%

Gemcitabine Plus Vinorelbine as the Second-Line Treatment and Beyond in Elderly Patients with Platinum-Pretreated Advanced Non-Small Cell Lung Cancer

Go¹,

Lee²,

Lee³

et al. 2014

Chemotherapy

View full text Add to dashboard Cite

Background: The efficacy and tolerance of a gemcitabine and vinorelbine (GV) combination as salvage therapy have not been reported in elderly patients with advanced non-small cell lung cancer (NSCLC). Methods: We reviewed elderly patients with advanced NSCLC who had disease progression after one or more chemotherapy regimens, at least one including platinum, and then who were treated with GV as the salvage therapy. Results: In total 40 patients were analyzed. GV was at least the third-line chemotherapy in 24 patients (60.0%). Only 2 patients (5.0%) experienced grade 3 febrile neutropenia. Nonhematologic toxicities were generally mild and there was no treatment-related mortality. Among 29 patients evaluable for treatment response, 10 (34.5%) and 9 (31.0%) achieved a partial response and stable disease, respectively. The median overall survival was 10.3 months and the median progression-free survival was 3.1 months. Conclusions: GV in combination is an effective and tolerable salvage regimen in elderly and heavily pretreated patients with advanced NSCLC.

show abstract

Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens

Cited by 34 publications

References 25 publications

A feasibility study of bevacizumab and vinorelbine in patients with previously treated advanced non-squamous non-small-cell lung cancer

A feasibility study of bevacizumab and vinorelbine in patients with previously treated advanced non-squamous non-small-cell lung cancer

Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study

Gemcitabine Plus Vinorelbine as the Second-Line Treatment and Beyond in Elderly Patients with Platinum-Pretreated Advanced Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About